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 ABSTRACT 
Acute lung injury remains a frequent and life threatening consequence of severe sepsis. 
This thesis has investigated the role of the endothelin (ET) system in sepsis-induced lung 
injury, with special reference to its effects on two hallmarks of this syndrome - formation 
of edema and pulmonary hypertension. This was explored in a porcine endotoxin model 
of sepsis in vivo, as well as in vitro using isolated porcine pulmonary vessels.  
In paper I we show that endotoxemia via ET-dependent mechanisms predominately 
increases pulmonary downstream resistance and subsequently augment pulmonary 
capillary hydrostatic pressure. In addition, we demonstrate that ETB-receptor stimulation 
constricts pulmonary veins more than arteries in vitro. In paper II, we show that 
endotoxin-exposure induces differentiated effects in isolated pulmonary arteries and 
veins. In veins, endotoxin increases ET-receptor dependent constriction, whereas the 
response to α1-adrenergic stimulation, predominantly acting on arteries, is reduced. In 
addition, we demonstrate that the changes in response to ET-receptor stimulation are not 
induced by alterations in expression or distribution of ET-receptors in the preparations. In 
paper III we find that inhalation of a dual ET-receptor antagonist, tezosentan, during 
porcine endotoxemia potently reduces pulmonary hypertension without causing systemic 
effects. In paper IV we show that endotoxemia induces a marked degranulation of 
polymorphonuclear neutrophils with increased plasma levels of the highly permeability 
and edema promoting heparin-binding protein (HBP/CAP37). Treatment with tezosentan 
distinctly counteracts this increase and simultaneously reduces pulmonary edema, 
improves respiratory system compliance and decreases hemoglobin concentration, all 
suggesting that tezosentan treatment reduces transcapillary fluid passage. 
In conclusion, our studies show that endotoxemia increases pulmonary capillary filtration 
pressure, raises levels of the powerful permeability promoting mediator HBP and induces 
pulmonary edema. Systemic treatment with a dual ET-receptor antagonist markedly 
counteracts these changes. In addition, inhaled tezosentan efficiently and selectively 
reduces pulmonary hypertension during endotoxemia. Taken together, these results show 
that the ET-system is extensively involved in the pathophysiology of endotoxin-induced 
lung injury. These findings need to be further elucidated, in other experimental conditions 
and in humans.  
Key words: acute lung injury, sepsis, endothelin, extravascular lung water, pulmonary capillary 
pressure, pulmonary edema, heparin-binding protein, CAP37, tezosentan, pig, pulmonary 
circulation 
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INTRODUCTION 
THE INJURED LUNG 
In 1967 a syndrome of severe and acute onset respiratory failure was described by 
Ashbaugh and Petty in the Lancet1. The condition was termed adult respiratory distress 
syndrome2. However, since this syndrome occurs at all ages, it was later renamed acute 
respiratory distress syndrome (ARDS) and its milder form acute lung injury (ALI). 
These are conditions characterized by a life threatening and acute onset respiratory 
failure that presents with progressive, severe arterial hypoxemia and dyspnea. 
Ultimately, oxygen demand exceeds ventilatory capability and the ensuing hypoxemic, 
hypercarbic, respiratory failure frequently leads to a requirement of endotracheal 
intubation, mechanical positive pressure ventilation and intensive care.  
Since ARDS and ALI are not uniform entities, but a syndrome with diverse clinical 
etiologies, the definition is based on specific criteria. These have been continuously 
reviewed in order to improve the precision of the definition3,4. In 1994 the American-
European Consensus Conference proposed a deﬁnition5, which was widely accepted as 
a tool for patient characterization and conduction of research trials. ALI and ARDS was 
defined as a syndrome of inflammation and increased permeability together with three 
diagnostic criteria: the presence of acute severe hypoxemia (deﬁned as a ratio of arterial 
oxygen tension over fractional inspired oxygen (PaO2/FiO2) < 300 mmHg (40 kPa) for 
ALI and < 200 mmHg (27 kPa) for ARDS), new and bilateral inﬁltrates on chest 
radiography and the absence of raised pulmonary artery occlusion pressure (PAOP). 
Although this definition is widely used, it has been subject to increasing criticism. As 
late as in October 2011 new criteria were presented6, aimed to better distinguish 
between the different severity levels of this syndrome. 
 
Epidemiology 
The estimated incidence and mortality of this syndrome varies significantly between 
reports, probably due to limitations of the diagnostic criteria and the varying 
background characteristics of the studied populations. In a US population, reported in 
2005, the incidence of ARDS was 59 per 100 000 person-years with an in hospital 
mortality of near 40 %7. A Scandinavian estimate published in 1999 was more 
conservative, with a reported incidence of ARDS of 13.5 per 100 000 person-years8. 
The 90 day mortality was 41%. These results are in line with a recent prospective 
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multicenter study from Spain, were the incidence was 7.2 per 100 000 person-years and 
the hospital mortality 48 %9. A substantial proportion of the survivors has a slow 
recovery, with up to 10 % of patients needing more than one month of mechanical 
ventilation10. Pulmonary function often recovers11,12, but the overall health may not 
improve completely, even in previously healthy patients13. In recent years a decline in 
the incidence and mortality of lung injury has been proposed14,15. This decrease has 
been attributed to advances in many aspects of care, such as ventilator and fluid 
management as well as improvements in diagnosis and treatment of infections. 
 
Pathogenesis and pathophysiology 
Several clinical conditions are associated with the acute development of lung injury, 
with serious infections such as pneumonia and sepsis as the most common predisposing 
illnesses7. Other important causes include aspiration of gastric contents and traumatic 
hemorrhagic shock or less common disorders such as acute pancreatitis, transfusion-
associated lung injury, near-drowning and drug reactions. The causes are often divided 
into two general pathophysiologic pathways: direct (pulmonary) or indirect 
(extrapulmonary) injury16. Direct injury refers to conditions in which the injurious 
event directly affects the lungs, such as diffuse pneumonia, aspiration pneumonitis, 
lung contusion or inhalation of noxious gases. In these situations the severity of the 
pulmonary injury is highly dependent on the grade of exposure to the noxious mediator. 
Indirect, extrapulmonary, lung injury refers to conditions were the primary disease is 
outside the lung, for example after multiple fractures, acute pancreatitis or non-
pulmonary sepsis. Comparison of outcome in pulmonary versus extrapulmonary 
triggers for the lung injury has demonstrated conflicting results, but suggests a trend 
towards higher mortality in the population with disease of pulmonary origin17. 
The course of lung injury is often divided into two main phases, starting with an early 
inflammatory response, known as the exudative phase, followed by prolonged healing 
process, known as the fibroproliferative phase18,19. The initial phase of lung injury is 
characterized by an acute inﬂammation that causes disruption of the pulmonary 
endothelial and epithelial barrier with subsequent vascular hyperpermeability. This 
change in permeability permits the efﬂux of protein-rich ﬂuid into the extra vascular 
interstitium, causing formation of interstitial and alveolar edema. The edema, in turn, 
disturbs gas-exchange, causes mismatch of ventilation/perfusion, reduces pulmonary 
compliance and increases the work of breathing. The late fibroproliferative phase is 
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characterized by a progressive organization of the exudates and hyaline membranes 
with interstitial fibrosis. In the lung, certain pathogenic processes are considered as 
especially important in the course of events leading to respiratory failure. 
 
Atelectasis 
When small airways in the inflamed and edematous lung parenchyma are collapsed or 
obliterated by stagnant secretions, the entrapped gas distally to the obstruction 
eventually will be resorbed. In addition, injuries to the alveolar epithelial type II cell 
reduce surfactant production which leads to impaired pulmonary compliance. Together 
these events results in collapsed, non-aerated lung parts and increased right-to-left 
shunting of deoxygenated blood. During the last decades the importance of using 
ventilator approaches that minimizes formation of atelectasis has been increasingly 
recognized20. 
 
Microthrombosis and neutrophil induced lung injury 
Post mortem angiographic studies and pathological examinations of ARDS patients 
have shown that macro- or microscopic thromboembolism and diffuse pulmonary 
endothelial injury is a frequent finding21. Even though lung injury may well develop 
in patients with severe neutropenia22, activation of polymorphonuclear neutrophils 
(PMN) are considered as important events in the pathogenesis of the disease. The 
concentration of PMN in bronchoalveolar lavage fluid of ARDS patients correlates 
with severity of disease and predict outcome23. Moreover, PMN have been shown to 
be crucial in various animal models of lung injury as PMN depletion or blocking of 
chemoattractants ameliorates lung injury24-26. During inflammation, endothelial cells 
exhibit increased activity of the transcription factor nuclear factor-κB (NF-κB), which 
up regulates the surface expression of adhesion molecules27. This mediates adhesion 
and migration of PMN across the endothelium to the alveolar epithelium. Activated 
PMN accumulate and release proinflammatory and procoagulant mediators, reactive 
oxygen species and proteases, which induce a loss of the normal endothelial barrier 
function. In addition, the release of potent metabolites of arachidonic acid, such as 
leukotrienes, prostaglandins and thromboxane, induces platelet and leukocyte 
aggregation and vasoconstriction. Together, these events cause obliterations of 
pulmonary capillaries with subsequent increments of dead space ventilation. 
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Ventilator-induced lung injury 
Mechanical ventilation may by itself induce injuries, denoted as ventilator-induced lung 
injury (VILI). Even though the inflamed and fragile lung most likely is more prone to 
suffer from VILI, it can also be induced in previously healthy lungs. VILI has been 
proposed to be a continuous phenomenon that manifest depending on the level and 
duration of the applied harmful stress28. The pathogenesis of VILI includes specific 
events that distress the lung; repeated recruitment and derecruitments of alveoli during 
the respiratory cycle induce shear stress (atelectotrauma) that not only injures the lung 
but also induces production of pro-inflammatory mediators that may induce distant 
harmful effects29. In addition, when aerated and less injured parts of the lung-
parenchyma are exposed to harmful levels of pressure, it causes over-distension and a 
further progression of lung injury. In summary, an increasing number of studies has 
revealed that a ventilation strategy with lower tidal volumes and lower airway pressures 
is protective to the injured lung30. Thus, in the past decades, strategies have been 
changed from preservation of normal blood-gases to a permissive approach aimed to 
protect the lung from secondary injuries, termed as lung-protective ventilation 
strategy10. 
 
Pulmonary hypertension 
Pulmonary hypertension is commonly recognized as a characteristic feature of lung 
injury31. In the early phase, pulmonary vasoconstriction in response to proinflammatory 
mediators, capillary obliterations and edema increase pulmonary vascular resistance 
(PVR) even following correction for the severity of the associated hypoxemia32. 
However, hypoxic vasoconstriction of precapillary arteries significantly augments PVR 
further. The resulting pulmonary hypertension increases right-ventricle outflow 
pressure that may reduce right ventricular function. In the later phases of lung injury, a 
ﬁbrocellular intimal proliferation occurs, involving predominantly small muscular 
arteries, but also veins and lymphatics which may contribute to edema formation21.  
 
Edema formation and resolution 
Formation of edema is considered as a hallmark of sepsis-induced lung injury19,33. The 
direction of fluid movement across a capillary membrane is determined by the 
properties of the membrane as well as the balance of the intra and extra-capillary 
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pressures. This is described by the classical but yet highly valid Starling equation of 
fluid filtration34:  
𝐽𝑣 = 𝑆 × 𝐿𝑝 �𝑃𝑐𝑎𝑝 − 𝑃𝐼𝐹 − 𝜎�𝜋𝑐𝑎𝑝 − 𝜋𝐼𝐹�� 
 
In the Starling equation, fluid flux (Jv, cm3 s−1) across a capillary membrane with a 
surface S (cm2) and a hydraulic permeability Lp (cm∙s−1∙cmH2O−1) is determined by the 
balance between the intra capillary hydrostatic (Pcap) and oncotic (πcap) pressure as well 
as the extra capillary intestinal fluid hydrostatic (PIF) and oncotic (πIF)  pressures. The 
reflection coefficient (σ) defines the endothelial permeability to protein (values from 0 
to 1; 0 when the capillary wall is fully permeable to proteins and 1 when the wall is 
impermeable to proteins). The hydraulic permeability varies between different vessel 
beds and is also highly affected by hormonal and immunological stimuli. 
Physiologically, due to the recoil properties of the layer of surfactant at the air-liquid 
interface of the alveolar space, PIF is slightly subatmospheric. Hence, the transmural 
filtration pressure (Pcap– PIF) is positive and only partly counteracted by the net oncotic 
pressure. Therefore, there is a continuous filtration of fluid across the capillary 
endothelium to the interstitial space. 
 
Hydrostatic edema 
If the pulmonary capillary hydrostatic pressure (i.e. the pulmonary capillary pressure, 
Pcap) is increased, the filtration of fluid increases to a point where the edema 
counteracting mechanisms are exceeded and a hydrostatic edema is formed. Pcap is a 
crucial determinant of filtration of plasma water across the capillary membrane and 
dependent on the mean pulmonary arterial pressure, the blood flow through the 
pulmonary circulation (cardiac output) and the pulmonary vascular resistance. 
However, the distribution of the pulmonary vascular resistance from precapillary 
(upstream, i.e. arterial), to the post capillary (downstream, i.e. venous) compartments 
varies and depending on the site where the constrictor effect dominates, pulmonary 
vascular constrictors may affect Pcap differentially. Thus, given an identical overall 
increase in pulmonary resistance, a constrictor with a predominantly venous site of 
action will generate a relatively higher capillary pressure with potential subsequent 
edema formation as compared with a constrictor with arterial predominance. Direct 
measurements of Pcap has not been made in human lungs but are estimated to be 5-10 
mmHg during physiologic conditions35,36. In intact animals the critical capillary 
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pressure at which fluid filtration exceeds edema counteracting mechanisms has been 
shown to be approximately 20 mmHg when oncotic pressure and permeability are 
normal37-38. 
 
Inflammatory edema 
The endothelium is a dynamic and highly active barrier that selectively regulates efflux 
of plasma fluid, macromolecules and leucocytes to the surrounding tissues39. In the 
early stage of inflammation, several inflammatory mediators, such as thrombin, 
bradykinin, leukotrienes and histamine, each may induce transient vascular leakage. At 
a later stage activation of the endothelium induces actin–myosin interactions with 
cytoskeletal disarrangements, causing loss of junctional integrity with formation 
intercellular gaps. This enhances endothelial permeability and causes vascular leakage, 
in particular in postcapillary venules. In addition, changes in intra- and extravascular 
vascular oncotic pressures are important for edema formation during inflammatory 
states. Plasma albumin accounts for 65% of πIF. However, as albumin also crosses the 
vascular barrier and may enter the interstitial tissue, it also serves as the main interstitial 
oncotic agent39. 
 
Edema counteracting mechanism 
In the lung, were edema is prone to interfere with gas-exchange, important edema 
counteracting mechanisms are present40. Normally, type I and type II alveolar epithelial 
cells form tight junctions with each other, selectively regulating the epithelial barrier. 
The primary mechanism that drives fluid reabsorption from the alveolar space into the 
interstitium and the pulmonary circulation is active transepithelial sodium ion 
transporting mechanisms41. This transport is thought to be primarily a function of 
alveolar type II cells42. Sodium ions enter the epithelial cells via amiloride-sensitive Na+ 
ion channels located on the apical membrane and subsequently “pumped” out at the 
basolateral side by the activity of the Na+/K+-ATPase. This transepithelial sodium ion 
transport creates osmotic forces which causes water to passively move from the air 
spaces to the alveolar interstitium via aquaporins to be subsequently removed via the 
lymphatic or capillary system. 
Injuries to the epithelium disrupt the barrier and might also impair normal alveolar fluid 
clearance via down regulation of Na+ channels and Na+/K+ ATPase pumps40,43. The 
mechanisms behind these changes are unclear but it has been shown that alveolar 
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edema fluid from ALI patients down regulates sodium ion transporting mechanisms 
and the expression of the responsible genes in cultured human alveolar epithelial type II 
cells44. In addition, it has been shown that alveolar fluid clearance is impaired in the 
majority of patients with lung injury and that high alveolar fluid clearance was 
associated with improved clinical outcomes, emphasizing the importance of alveolar 
fluid resolution45. 
The pulmonary lymphatic system constitutes of small contractile vessels that drive 
excess fluid toward regional lymph nodes in the pulmonary hilum, aided by breathing 
movements and valves. The lymphatics can increase their edema clearance rate several-
fold, but only up to a critical value. Formation of pleural fluid is also considered as a 
protective mechanism against pulmonary edema formation46. 
 
Treatment of lung injury 
Since the early descriptions of ARDS and ALI, considerable basic and clinical research 
have been conducted aimed to find specific therapies, most of them proved futile47. 
However, despite the lack of specific therapies, mortality is suggested to be declining15. 
This is probably due to increased knowledge on the importance of early diagnosis and 
goal-directed treatments of underlying conditions as well as general improvements in 
intensive care. In addition, the increased awareness on VILI has contributed to 
improvements in ventilator strategies. As formation of edema is a significant part in the 
pathogenesis optimal fluid management is central. In 2006 a controlled trial showed 
that the use of a conservative fluid-management protocol improved lung function and 
shortened the duration of mechanical ventilation as well as intensive care, without 
increasing non-pulmonary organ failure48. 
 
SEPSIS 
Definitions, epidemiology and pathophysiology 
Sepsis is considered as the systemic inflammatory response to infection49. However, the 
definition of sepsis has been changing over time. In 1992 a consensus definition was 
presented by Bone et al50. Sepsis was here defined as a systemic inflammatory response 
to a confirmed or suspected infection; severe sepsis as sepsis with organ dysfunction; 
and septic shock as sepsis with persistent hypotension despite adequate fluid 
resuscitation. Systemic inflammatory response syndrome is a criterion based 
description of widespread inflammation; the underlying condition may be infection but 
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severe systemic inflammation can also be a seen in patients suffering from tissue 
damage after traumatic injuries, major surgery, burns, acute pancreatitis or 
inflammatory disease. 
The incidence and mortality of severe sepsis varies between studies and over time51. In 
reports from Scandinavia, the incidence of severe sepsis varies from 0.38 to 1.49 per 
1000 person-years52-54. The incidence of severe sepsis has been reported to increase 55. 
Several factors have been suggested to contribute to this; an ageing population, often 
living with chronic diseases, an increasing use of invasive procedures in modern 
medicine and a growing number of conditions treated with immunosuppressive drugs. 
Despite intense efforts to reduce mortality of severe sepsis it remains high, with 
hospital mortality rates between 20 and 30% in reports from Sweden and Finland52,53. 
Patient related factors that are associated with increased mortality in severe sepsis 
include advanced age, severity of illness and comorbidities such as kidney failure.  
During the recent decade, the theory proposing that the cause of sepsis is the body’s 
own uncontrolled inflammatory response to infection56, has been partly questioned57. 
The pathophysiology of the sepsis syndrome is heterogeneous and the dominating 
pathological mechanisms in a patient may vary over the time as well as between 
patients. In sepsis several major pathways are disturbed, including the 
immune/inflammatory cascades, procoagulant/antifibrinolytic pathways, cellular 
metabolism and vascular permeability33. This results in an early hyperinflammatory, 
procoagulant state, with a concomitant or subsequent prolonged condition with immune 
dysfunction (Figure 1.)58. 
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Endotoxin and Toll-like receptors 
Endotoxin is a lipopolysaccharide (LPS, Figure 2.) component of the outer cellular 
membrane of Gram-negative bacteria. Endotoxin consists of three parts, an outer 
variable polysaccharide O side chain (the O-antigen), a core region and a highly 
conserved lipid A component. All components of LPS are required for the virulence of 
Gram-negative bacteria but only the lipid A is essential for the integrity of the cell 
wall59. Variation within the length of the O-antigen can change the phenotypic 
appearance (i.e. smooth or rough) of the bacterium as well as the bioactive response of 
the host to the bacterium itself60. The primary active component of LPS, the lipid A 
residue, is a normally embedded in the cell membrane, but released when bacteria are 
either multiplying or being destroyed. In the infected tissues, lipid A is opsonized by a 
lipopolysaccharide-binding protein forming a complex, which in turn is bound by the 
receptor CD14 on the surface of host cells.  
 
Figure 2. Schematic illustration of the 
lipopolysaccharide molecule with its three 
domains; the O-antigen that is comprised of a 
repeating oligosaccharide, the core - a 
nonrepeating oligosaccharide, and lipid A - a 
hydrophobic anchor.  
Figure. 1. Illustration of the immunoinflammatory response of three hypothetical patients with 
sepsis. The individual immune response in sepsis is determined by many factors, including 
pathogen characteristics, size of the bacterial inoculum and patient comorbidities. The initial 
immune response is hyperinflammatory, but the response rapidly progresses to 
hypoinflammatory. In the healthy individual who experiences meningococcemia, there is a 
powerful, detrimental, hyperinflammatory response. In this situation antiinflammatory treatments 
might improve survival.  In the elderly patient with malnutrition who experiences intraabdominal 
infection, the initial inflammatory response is limited, and if the infection persists, a prolonged 
hypoinflammatory response develops.  In the patient with diabetes, chronic renal failure, and 
pneumonia, the initial response is blunted, and there is a prolonged depression of immune 
function. Reproduced with permission from Skrupky et al: Advances in the Management of 
Sepsis and the Understanding of Key Immunologic Defects. Anesthesiology 2011; Vol.115 - 6 - 
p 1349–1362  
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This complex induces a transmembrane signal mediated through activation of the Toll-
like receptor 4 (TLR4), first described by Beutler et al in 199861 (awarded with the 
Nobel Prize in Physiology or Medicine 2011). The TLR4-pathway is of vital 
importance for the host reaction to LPS; disruption of the TLR4-pathway in animals 
totally abolishes the reaction to LPS but makes them highly susceptible to Gram-
negative infections62. TRL4 is expressed in several tissues, but the detrimental effect of 
LPS is considered primarily to be mediated via activation of macrophages63. However, 
it has also been shown that endothelial TLR4 can act as an important sentinel for 
circulating Gram-negative bacteria64. 
TLRs are transmembrane proteins with three sections: an extracellular domain that 
mediate the recognition of so called pathogen-associated molecular patterns (PAMPs), 
a transmembrane domain and an intracellular Toll–interleukin 1 receptor domain which 
is required for downstream signal transduction65. After binding the TLR4-LPS complex 
is internalized and triggers signal transduction which leads to an activation of the 
transcription factor family NF-κB and mitogen-activated protein kinases. They, in turn 
induce production of inflammatory cytokines and enzymes, which during sepsis sets a 
massive proinflammatory response in motion with activation of complement and 
coagulation cascades65. 
Endotoxin is considered an important constituent of the pathophysiology of Gram-
negative bacterial sepsis. Clinical studies in patients with severe sepsis have shown that 
patients with increased concentrations of endotoxin at study entry had notably higher 
mortality than those without measurable endotoxin levels66. Moreover, endotoxin-
clearing therapies using polymyxin B-hemoperfusion has been reported to improve 
hemodynamic-stability in patients with abdominal sepsis67. Humans given very low 
concentrations of endotoxin show signs and symptoms of clinical sepsis68. In addition, 
in an anecdotic report, self-administration of a massive dose of endotoxin in one 
patient, resulted in a sepsis-like hyperdynamic shock with disseminated intravascular 
coagulation and multiple organ dysfunction69. 
 
Treatment of sepsis 
Due to the considerable morbidity and mortality of sepsis, substantial effort has been 
put into research to find effective therapies. Most of these therapies have been proved 
futile once tried in the clinical setting70,71. The reasons for the lack of effective anti-
mediator treatments have been suggested to relate to the vast heterogeneousity of sepsis 
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patients with probable differences in immune response, both among patients and over 
time in the same patient72. However, during the last decade less elaborate approaches 
using early and adequate antibiotic treatment, prompt control of the sources of  
infection and goal directed fluid therapy has been shown to reduce mortality in 
sepsis73,74. 
 
THE ENDOTHELIN SYSTEM  
In 1985, Hickey et al reported that isolated arteries contracted in response to exposure 
to the medium of cultured endothelial cells75. The active substance, at that present 
suggested to be a peptide but otherwise was of unknown nature, was later denoted 
“endothelium-derived contractile factor” (EDCF) in contrast to the “endothelium-
derived relaxing factor” (EDRF) discovered by Furchgott et al in 198076 and later 
found to be NO77. In 1988, Yanagisawa et al isolated and characterized an endogenous 
and highly vasoconstrictive peptide found in the culture medium of porcine aortic 
endothelial cells78. The peptide was named endothelin-1 (ET-1, Figure 3.). In a series 
of experiments this group showed that ET-1 was produced by the endothelium and 
exerted its potent constrictive (1000 time more potent than noradrenaline79) effects by 
stimulating the underlying smooth muscle cells. In the following decades the research 
field regarding the endothelin system has expanded dramatically and endothelin has 
been shown to be involved not only in cardiovascular physiology and disease80, but also 
in other pathological conditions such as sepsis81,81, diabetes82, pain83 and malignancy84. 
 
 
 
 
 
 
Cellular biosynthesis and release  
In humans the endothelin family consists of three closely related peptides, denoted ET-
1, ET-2 and ET-385. In addition to these, a group of venoms isolated from the Israeli 
Burrowing asp (Atractaspis endgaddensis), called sarafotoxins, have been identified as 
members of this family86. The three human ETs are all 21 amino acids in lengths, but 
encoded by different genes located on chromosomes 6, 1 and 20 respectively. ET-1 is 
recognized as the major isoform of relevance in human cardiovascular 
Figure 3. Schematic structure of 
the human and porcine 
endothelin-1 molecule. 
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pathophysiology87 and is therefore the focus of this thesis. ET-2 is primarily produced 
within the kidney and the intestine, whereas ET-3 is predominately found in the central 
nervous system; however the roles of ET-2 and ET-3 are largely unclear. 
ET-1 is mainly produced and released by the vascular endothelial cells88, but 
production has also been described in several other tissues including lung, kidney, 
heart, leucocytes and brain89-92. ET-1 is generated in a two-step proteolytic process 
from a large (human 212, porcine 203 amino acid residues93) precursor peptide, 
preproET-184. PreproET-1 is cleaved by endopeptidases to a 39 amino acid peptide 
denoted big-ET-1, which possesses weak vasoconstrictive properties. Big-ET-1 is 
further converted by a family of intracellular membrane bound zinc metalloproteases, 
endothelin converting enzymes, to ET-1 which forms a loop closed by two disulfur 
bonds. The structure of human and porcine ET-1 is identical. From the endothelium 
there is a continuous and constitutive release of ET-1 which there by contributes to 
regulation of basal vasomotor tone94,95. However, the peptide is also stored in granules 
in the endothelial cells. Synthesis and release of ET-1 is stimulated by to various 
physiological and pharmacological stimuli96 such as catecholamines78, angiotensin-II97, 
cytokines98, insulin99, thrombin100, tumor necrosis factor-α101, hypoxia102, acidosis and 
ET-1 itself103 (Figure 4.). Factors that inhibit production and secretion of ET-1 include 
NO104, heparin105, prostacyclin106 and vascular shear stress107. ET-1 is considered 
foremost to act in a paracrine/autocrine fashion since the majority of its production is 
released by the endothelial cells abluminally toward the underlying interstitial space 
and the smooth muscle cells108. A minor portion is detected in the plasma, suggesting 
that elevated circulating levels principally represent an overflow of tissue ET-1 and 
only can been seen as an approximation of true ET-1 activity. However, in pathological 
conditions with high circulating levels of ET-1, it may act as an endocrine factor109. 
Plasma clearance of circulating ET-1 is rapid with a biological half-time of 1-2 
minutes110. The pulmonary circulation acts as a major clearance site of ET-1111, with a 
near 50% single-pass extraction of plasma ET-1 in the pulmonary circulation of normal 
human subjects112. However, as the lungs produce significant amounts of ET-1, there is 
no or minimal arterio-venous ET-1-gradient across the pulmonary circulation. Even 
though half-time of ET-1 is short, the physiological response, such as vasoconstriction, 
is sustained and lasting 1-2 hours113. 
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Receptors and intracellular signal transduction 
The effects of ET are mediated via three main subtypes of ET-receptors, denoted ETA, 
ETB and ETC. ETC-receptors have not been found in mammalian tissues. ETA and ETB 
receptors share about 60 % amino acid homology but are encoded by separate genes 
located on chromosome 4 and 13, respectively. The ETA-receptor has 10 times more 
binding affinity for ET-1 and ET-2 than ET-387, while the ETB-receptor has equal 
affinity to all the three ET-peptides. The ETA-receptor is predominantly expressed on 
vascular smooth muscle cells, mediating a powerful and long lasting contraction as well 
as cell proliferation. The role of the ETB-receptor is more complex and dependent on 
their localization. ETB-receptors are primarily located on the endothelium, mediating 
vasodilatation through the release of NO and prostacyclin114,115. In addition, endothelial 
ETB-receptors clear ET-1 from the circulation via endocytosis of the receptor-ligand 
complex with subsequent degradation in lysosomes116. However, ETB-receptors are 
also situated on smooth muscle cells and mediate contraction. Under physiological 
conditions the dominating effect of ET-1 is considered to be an ETA-receptor mediated 
vasoconstriction, partially balanced by ETB-receptor mediated vasodilation through the 
release of NO. The effects of ET-1 on various vascular beds depend on the local 
receptor subtype distribution, which not are uniform and may also change during 
pathological conditions117,118. 
Genetic knockout experiments have revealed that the ET-system is highly involved in 
normal embryonic development. Mice lacking ET-1, ECE-1 or the ETA-receptor 
receptor die at birth due to mechanical asphyxia resulting from severe malformation in 
structures derived from the mandibular arch, arches of lower jaw and throat 
structures119-121. Mutations in the gene encoding the ETB-receptor produce congenital 
pigment abnormalities and aganglionic megacolon, with neonatal lethality around 3 
weeks in mice, suggesting that the ETB-receptor plays an important role in the normal 
development of the neural crest122. In addition, the ETB-receptor has been suggested to 
be involved in mediation of inflammatory pain and cutaneous inflammatory responses 
in mice123. In humans, mutations in the ETB-receptor gene are associated with a variant 
of the human genetic disease Hirschsprung syndrome124. 
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Both endothelin-receptors belong to the G protein-coupled receptor superfamily. ET-1 
binding to constrictive ETA and ETB-receptors results in activation of phospholipase C 
which hydrolyses phosphatidyl inositol to form the two second messengers’ inositol 
triphosphate (IP3) and diacylglycerol (DAG)125. IP3 and DAG activates calcium-
channels causing release of Ca2+ from the sarcoplasmic reticulum and Ca2+ inflow from 
the extracellular space. Ca2+ activates myofilaments and induces smooth muscle 
contraction. In addition, ET-1 activates nuclear signal transduction cascades that induce 
gene transcription, mediating the mitogenic and hypertrophic effects of ET-1. ET-1 
stimulates tyrosine kinase activity leading to induction of growth promoting proto-
oncogenes and mitogen-activated protein kinases. ET-1 may also activate 
phospholipase A2 inducing release of thromboxane A2 and prostaglandins from 
arachidonic acid126. 
Figure 4. Pathways of endothelin-1 (ET-1) synthesis and sites of action. The synthesis and 
release of ET-1 from the endothelium is influenced by various factors of different nature. 
Abbreviations: ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; ETA, ETB 
endothelin receptor A and B; IL-1, interleukin-1; LDL, low density lipoprotein; TGF-β, 
transforming growth factor β. For details, see text. Reproduced with permission from Dhaun et 
al. Trends Pharmacol Sci. 2007 Nov;28(11). 
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The endothelin-system and the lung 
In peripheral human lung tissue ETA:ETB receptor ratio is approximately 30:70, 
however the distribution within the parenchyma is not uniform127. Generally, ET-
receptors are predominantly found on smooth muscle cells and in alveolar walls128. In 
the human pulmonary circulation, ETA is dominating in larger arteries with increasing 
ETB proportion in more distal arteries117. The ETB receptor is the predominant receptor 
subtype present in proximal bronchial smooth muscle129.  
ET-1 levels has been shown to be elevated in plasma130-132 as well as in the epithelial 
lining fluid of patients with ARDS and to correlate with severity of lung injury133. In 
addition, ET-1 and albumin concentration in epithelial lining fluid correlated, 
suggesting increased endothelial and epithelial permeability. ET-1 has been show to 
increase vascular permeability of the bronchial vascular bed134 and plasma levels of 
ET-1 has been shown to correlate with extravascular lung water in patients with septic 
shock and acute lung injury135. In addition, endothelin receptor antagonists has been 
suggested to possess antifibrotic properties in pulmonary fibrosis136. 
 
The endothelin-system and sepsis 
Several investigators have shown increased levels of ET-1 in patients with sepsis and 
septic shock109,137-141. The level of ET-1 in septic shock is much higher than that seen in 
cardiogenic shock142 and higher than expected for the degree of hypotension143 which 
implies that the elevation of ET-1 cannot be explained by the hypotension in itself. The 
ET-system is considered to be involved in several of the pathogenic processes of sepsis. 
Besides possessing powerful vasoconstricting properties, ET-1 activates leucocytes, 
increases leukocyte adhesion and promotes production of proinflammatory 
mediators144. In experimental sepsis, ETRA has been show to improve cardiac, 
pulmonary and renal functions as well as splanchnic microvascular perfusion 145-151. 
 
Endothelin-receptor antagonists and their clinical use  
Endothelin receptor antagonists (ETRA) have played a key role in the exploration of 
the physiology and pathophysiology of the endothelin system. ETRA are classified 
both by their pharmacodynamics (selectivity) and their structural characteristics 
(peptide/non-peptide). Selective ETRA are compounds that exhibit at least 100-fold 
greater affinity for one of the ET-receptor subtype than the other94. The first developed 
ETRA were small peptides (denoted BQ-123152 and BQ-788153). However, the peptidic 
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nature of the compounds restricted their use to mainly mechanistic studies, often in 
small animals. Bosentan (Ro 47–0203), a non-selective/dual ETRA, non-peptidic 
ETRA, was the first ETRA to find clinical use154. The number of ETRA has expanded 
and there are now several non-peptidic ETRA engaged in numerous clinical trials 
targeting the ET-pathway for patients suffering from a range of disorders, including 
malignancy, pain, atherosclerosis and myocardial infarction155,156.  At present the major 
clinical field for ETRA treatment is chronic pulmonary hypertension where these drugs 
have been show to improve hemodynamics, counteract right ventricular hypertrophy 
and to improve pulmonary arterial remodeling157. 
 
HEPARIN-BINDING PROTEIN (CAP37/AZUROCIDIN) 
Heparin-binding protein (HBP) is a PMN-derived granule protein that is considered as 
a key mediator in PMN induced hyperpermeability158. In 1984 Shafer et al isolated a 
protein with anti-microbial properties from the granules of human PMNs159. Due to its 
size and charge the protein was named cationic antimicrobial protein 37 (CAP37). 
Later, azurocidin was identified as a protein with bactericidal properties stored in 
azurophilic (primary) granule of PMN160. Flodgaard et al isolated a protein from human 
and porcine PMNs with the ability to bind heparin, hence the name heparin-binding 
protein161. Sequencing confirmed that CAP37, azurocidin and HBP are the same 
protein and revealed the proteins resemblance to other members of the serprocidin 
family162. These are serine proteases which have a conserved catalytic active site 
consisting of histidine-57, aspartate-102 and serine-195. In the HBP molecule two 
amino acid residues has been replaced, rendering an enzymatically inactive protein. 
However, instead of proteolytic activity, HBP possesses several other important 
properties. Initially most interest was directed to HBPs broad antimicrobial effects but 
later more attention has been focused on HBPs function as a paramount mediator of 
PMNs immune-modulating and permeability increasing effects158. 
HBP is contained within two different granule subsets, azurophilic/primary granules 
and secretory vesicles163. Primary granules have a lower propensity for release and are 
considered to primarily be secreted and acting in the extra vascular space at the site of 
inflammation. The other granule subset containing HBP, the secretory vesicles, are 
instead localized close to the PMN cell surface and are promptly mobilized and 
secreted already in the bloodstream upon stimulation. 
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HBP is the only granule protein that is secreted from secretory vesicle163, which allows 
an almost instant permeability change of the endothelium upon neutrophil activation. 
This exclusive intracellular localization might be one aspect of HBPs function as a vital 
mediator in PMN induced in permeability changes158. Recently HBP has gained 
attention as a biomarker to predict circulatory failure in febrile patients with suspected 
infection164. The notion that high plasma concentrations of HBP are associated with 
circulatory instability in severe infections, suggests that this protein might be an 
important mediator of vascular leakage and subsequent hypovolemia in sepsis. 
However, the exact mechanisms by which HBP activates signaling pathways in the 
endothelial cells that causes reversible cytoskeletal changes remain elusive. HBP has a 
strong dipole moment due to the concentration of positively charged amino acid 
residues on one side of the molecule165. It has been suggested that HBP induces 
endothelial permeability changes through an interaction between the positive patch of 
HBP and the negatively charged proteoglycans on the endothelium166. In addition, 
deposited HBP induces synthesis of cell adhesion molecules on the endothelial cells167. 
Together, these events cause disruption of the endothelial barrier with subsequent 
leakage of plasma fluid and facilitation of leukocyte rolling and migration through the 
vessel wall158. Moreover, HBP potently attracts and activates monocytes as well as 
potentiates endotoxin-induced production of proinflammatory cytokines168,169. 
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AIMS OF THE THESIS 
The overall aim of this thesis was to investigate the role of the endothelin system in 
experimental lung injury with focus on vascular responses and edema formation. The 
specific aims were: 
 
⋅ To study the effects of ET-receptor stimulation on pulmonary arteries and veins 
in vitro and on pulmonary capillary pressure and pulmonary up- and 
downstream vascular resistances in vivo. 
 
⋅ To determine the effects of endotoxin on pulmonary capillary pressure and 
pulmonary up- and downstream vascular resistances in vivo. 
 
⋅ To investigate the effect of endotoxin on contractile and relaxing responses in 
isolated pulmonary arteries and veins. 
 
⋅ To study the effects of inhaled and systemically administered dual ET-receptor 
antagonist on pulmonary and systemic parameters during endotoxemia. 
 
⋅ To investigate the effects of a graded ET-1 challenge in non-endotoxemic pigs 
and dual ET-receptor antagonism during endotoxemia on plasma levels of 
heparin-binding protein and formation of extravascular lung water. 
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MATERIAL AND METHODS 
For detailed descriptions of the used materials and methods, the reader is referred to the 
respective publications of this thesis. 
 
ANIMAL ANESTHESIA, PREPARATION AND INTERVENTIONS  
Domestic landrace pigs (Sus scrofa domesticus) of both genders with weights 26-36 kg 
and age 60-120 days were used in all three in vivo studies. The animals were fasted 
over night with free access to water. In paper I the animals were pre-medicated with 
intramuscular injections of ketamine 20 mg·kg-1 and atropine 25 µg·kg-1, in paper III 
and IV with intramuscular injections of medetomidin 40 µg·kg-1, zolazepam 1 mg·kg-1 
and atropine 25 µg·kg-1. Anesthesia was induced with pentobarbital 12 mg·kg-1 
intravenously and maintained thereafter by continuous infusions of  ketamine 20 
mg·kg-1·h-1, midazolam 0.4 mg·kg-1·h-1 and fentanyl 10 µg·kg-1·h-1 (paper I), ketamine 
20 mg·kg-1·h-1, midazolam 0.6 mg·kg-1·h-1, fentanyl 20 µg·kg-1·h-1 and cisatrakurium 
0.125 µg·kg-1·h-1 (paper III)  and  ketamine 8 mg·kg-1·h-1, midazolam 0.5 mg·kg-1·h-1 
and fentanyl 18 µg·kg-1·h-1 (IV). Single bolus doses of pancuronium 0.25 mg·kg-1 were 
given prior to tracheotomy and if necessary an additional dose was administered during 
cautery in order to facilitate surgical preparation. Anesthetic level was evaluated before 
the administration of muscle relaxants by painful stimuli to the fore hoof with a forceps. 
Continuous infusions of isotonic saline at a rate of 20 (I) or 30 (III and IV) mL∙kg-1∙h-1 
were administered throughout the experiments. Body temperature was maintained at 
38-39°C by heating pads. The animals were placed in supine position, tracheotomized 
and ventilated using volume-controlled ventilation with a respiratory frequency of 18 
min-1, tidal volumes adjusted to achieve normoventilation at baseline and a positive 
end-expiratory pressure of 5 cmH2O. After surgical preparation the animals were 
allowed to stabilize for 30 minutes before the endotoxin infusion was started. At the 
end of the experiments the animals were euthanized by a lethal dose of pentobarbital in 
ethanol. 
 
Endotoxin 
In the in vivo experiments (paper I, III and IV), Escherichia coli serotype 0111:B4 
(Sigma-Aldrich Sweden AB, Stockholm, Sweden) lipopolysaccharide was used. In 
paper I, the endotoxin infusion rate was increased during the initial phase and titrated to 
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obtain an increase in mean pulmonary arterial pressure above 30 mmHg (mean rate 0.2 
μg∙kg–1 h–1, range 0.16–0.5). In paper III and IV, the animals received an infusion 
beginning at 0.05 µg∙kg–1 ∙h–1 then gradually increased to reach 0.25 μg∙kg–1∙h–1 within 
30-45 min. The infusions were continued during the whole experiment until 
termination of the protocols after 5 h. 
In paper II, the vessels were incubated in medium containing endotoxin from 
Escherichia coli serotype 0127:B8 (Sigma-Aldrich Sweden AB, Stockholm, Sweden) 
at a concentration of 10 mg∙mL-1. 
 
Tezosentan  
Tezosentan (Figure 5.) belong to the sulfonamide class of ET-receptor antagonists. It is 
a competitive, potent and highly water-soluble ET-receptor antagonist designed for 
parenteral use170. Tezosentan has an affinity to ETA and ETB- receptors respectively of 
30:1 and is thus considered as an unselective, dual antagonist. The distribution half-life 
of tezosentan in humans is 0.1 hours and the elimination half-life 3 hours. The primary 
elimination mechanism is biliary excretion of unchanged compound, even though some 
metabolism occurs by hydroxylation171. The effect of tezosentan metabolites is low and 
no accumulation has been reported.  
When used in humans, the main side effect is headache, suggested to be due to cerebral 
vasodilation. Tezosentan has been studied in phase III clinical trials aimed to treat acute 
congestive heart failure172,173. In these studies no favorable effect of treatment were 
found and the main side effect was systemic hypotension. 
 
 
 
In the publications of this thesis, tezosentan (Actelion Pharmaceuticals Ltd, Allschwil, 
Switzerland) was dissolved in saline on the day of the experiment. In paper I tezosentan 
was administrated as a bolus of 1 mg·kg-1 over 10 minutes followed by a continuous 
Figure 5. The molecular formula of 
the dual endothelin receptor 
antagonist tezosentan. 
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infusion at 1 mg·kg-1·h-1 for one hour. In paper III tezosentan was administered as a 
bolus of 0.5 mg·kg-1 i.v. or inhaled or 0.05 mg·kg-1 inhaled, all during 20 minutes. In 
paper IV tezosentan was administrated as a bolus of 1 mg·kg-1 over 10 minutes 
followed by a continuous infusion at 1 mg·kg-1·h-1 for three hours. 
In paper III plasma concentrations of tezosentan were analyzed by reversed-phase ultra 
performance liquid chromatography and tandem mass spectrometry after protein 
precipitation with acetonitrile, an method slightly modified from original description of 
the analysis described by van Giersberger et al174. 
 
Endothelin receptor agonists and phenylephrine 
Synthetic ET-1 (American Peptide Co., Sunnyvale, CA, USA) was used in paper I, II 
and IV. In paper I, the average dose used was 35 ρmol∙kg-1∙min-1 (range 15- 65); due to 
variability in response the dosage was adjusted in order to get significant, but not 
detrimental increases in pulmonary vascular resistance. In paper IV, an intravenous 
infusion of ET-1 was started at 10 ρmol·kg-1·min-1 and increased to 20 ρmol·kg-1·min-1 
after 90 min. 
Sarafotoxin 6c (S6c, American Peptide Co., Sunnyvale, CA, USA) was used in paper I 
and II. In paper I the average infusion rate was approximately 30 ρmol∙kg-1∙min-1. 
In the myographic experiments (paper I and II), concentration-response relationships 
for ET-1 and S6c was recorded using concentrations between 10-11   and 10-6,5 M. 
Phenylephrine (Apoteksbolaget AB, Stockholm, Sweden), a selective and synthetic α1-
adrenergic agonist was used in the myographic experiments as well as a reference 
substance in paper I. The infusion rate in vivo was 2 µg·kg-1·min-1, a dose within the 
range of clinical use. 
 
Biochemical analyses of plasma ET-1, HBP and myeloperoxidase 
In paper III and IV, arterial plasma levels of ET-1 immunoreactivity were analyzed 
with radioimmunoassay as described previously175. Arterial plasma levels of HBP were 
analyzed with an enzyme-linked immunosorbent assay163. Briefly, multi-well plates 
were coated with a monoclonal antibody against porcine HBP diluted in a buffer 
solution. Plates were washed with phosphate-buffered saline containing Tween 20 and 
were thereafter blocked with washing buffer containing bovine serum albumin 
(incubation buffer) for 30 minutes at 37°C. This was followed by incubation with 
samples containing porcine plasma HBP or a serial dilution of a HBP standard (1.95-
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250 ng∙mL-1) which were added to the incubation buffer for 1 h at 37°C. After a 
washing step, the plates were incubated with a polyclonal antibody against porcine 
HBP. Bound antibody was detected by a horseradish peroxidase-labeled secondary 
antibody against rabbit-IgG and a chromogenic substrate solution. Each incubation step 
was followed by a washing step. Arterial plasma levels of myeloperoxidase (MPO) 
were analyzed with enzyme-linked immunosorbent assay for porcine myeloperoxidase 
(Uscn Life Science Inc., Wuhan, China) in accordance with instructions from the 
manufacturer. 
 
Nebulization 
In paper III a standard ultrasonic nebulizer (Servo Ultra Nebulizer 345, Maquet, Solna, 
Sweden) was used. The nebulizer provides aerosol particles with a mean mass 
aerodynamic diameter of 4.7 µm, the lower tenth percentile at 2.4 µm and the higher at 
8.6 µm (data from manufacturer, Maquet, Solna, Sweden). The administered volume of 
4 ml was completely nebulized after 20 minutes. 
 
ASSESSMENTS OF EXTRAVASCULAR LUNG WATER 
As formation of edema is a major issue in development of lung injury, measurements of 
extravascular lung water (EVLW ) are considered as an potentially valuable parameter 
in pulmonary dysfunction176. Accordingly, significant efforts have been made aimed to 
develop methods which would provide accurate bedside measurement. However, so far 
no method has gained widespread acceptance, mainly due to uncertainty regarding the 
accuracy of bedside EVLW measurements in patients with heterogeneous lung 
perfusion177. 
  
Single Thermal Indicator Dilution Method  
The commercially available single thermal indicator dilution system (PiCCO®, Pulsion 
Medical Systems AG, Munich, Germany) was used. A thermistor-tipped arterial 
catheter placed in the lower abdominal aorta through a cut down of the femoral artery. 
The single thermal indicator dilution (STID) technique has been described previously178 
and been validated in experimental settings179-181. Each EVLW measurement was 
determined by the average of three injections of 10 mL of ice-cold saline to a central 
vein. EVLW was presented as indexed to body weight (EVLWISTID). 
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Gravimetrical analysis 
The gravimetrical method is considered as the golden standard of EVLW assessments. 
However, the gravimetrical method has a major drawback as it demands extraction of 
the lungs and therefor only provides a single value at the end of the experiment. The 
method was performed in accordance with the original procedure described by 
Pearce182 with the modification in ultracentrifugation according to Selinger183. After 
termination of the protocol a sternotomy was performed and both lung hili was located. 
A large volume sample of blood was drawn from the central line for determination of 
hemoglobin concentration, hematocrit and wet to dry weights of the blood. Thereafter 
the animals were euthanized followed by immediate clamping and removal of the 
lungs. After passive drainage of blood, the lungs were weighed and homogenized with 
an equal amount of deionized water. Half of the homogenate was used to determine its 
wet to dry weight and the other half was centrifuged at 30 000 g for 1 h at 4°C. The 
supernatant was separated, and its hemoglobin concentration and wet to dry weight 
were determined. The dry weights of the blood, homogenate, and supernatant were 
determined after 72 hours of incubation in a heat chamber at 85°C. EVLW was then 
calculated and indexed to body weight (EVLWIGrav, for equations see Appendix). 
 
MEASUREMENT OF PULMONARY CAPILLARY PRESSURE 
As mentioned before, even though Pcap is of significant interest due to its impact on 
edema formation is it not possible to directly measure Pcap in patients or intact 
animals. Therefore the arterial occlusion technique has been developed184. According 
to this method, the pulmonary circulation may be described as an electric circuit 
where the pulmonary vascular resistance is represented by two resistors in series, one 
pre- and one post capillary. The capillary blood volume, which composes a major 
portion of the total pulmonary blood volume, is represented by a capacitor at the 
capillary level. When the circuit is broken precapillary (i.e. the artery is occluded by 
the balloon in systole) the current first drops rapidly to reach the level of the current 
in the capacitor, then more slowly when the capacitor is discharged to finally reach 
the pulmonary venous pressure. 
The pulmonary arterial occlusion method for determination of Pcap is based on 
assessment of the shape of the pulmonary artery pressure decay curve during balloon 
occlusion using a pulmonary artery catheter with an inflatable balloon. The occlusion 
should be performed in the systolic upstroke, during an expiratory hold to avoid the 
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effect of changes in intrathoracic pressure and lung volume on the pressure curve. 
After occlusion, there is a rapid decline in the pressure distally to the balloon, 
followed by a slower pressure decrement approaching the pulmonary artery occlusion 
pressure (Figure 6.). When a straight line is drawn tangent to the rapid component 
pulmonary capillary pressure can be estimated as the inflection at which the pressure 
transient begins to deviate from the rapid portion of the pressure tracing. The use of a 
time constant and a bi-exponential curve fitting has been suggested to improve the 
accuracy of the measurement185. 
In our experiments, ordinary pulmonary artery catheters (Edwards Life Science, St. 
Ana, CA, USA) were modified in order to allow simultaneous measurements of 
pressures at the tip and two centimeters proximal of the balloon. The recordings were 
sampled at 1000 Hz with a digital data acquisition system (Acqknowledge, Biopac 
Systems, Santa Barbara, CA, USA). The measurements were performed in an 
extended expiratory pause and repeated balloon occlusions were performed in 
sequence at each point of registration in order to obtain adequate curves with a 
distinct point of occlusion in systole. The tracing of the pressure decay from the time 
of occlusion and 4000 ms was fitted to a biexponential function in order to determine 
the Pcap at 175 ms, all according to description by Pellet et al185. Only curves with an 
accurate systolic occlusion point and without significant artifacts were used. Pcap was 
used to calculate pulmonary up- and downstream vascular resistance index using 
standard formulas (presented in the Appendix). 
 
 
 
Figure 6. Representative pressure tracing recorded during porcine endotoxemia with a 
modified pulmonary artery catheter. Pressure tracing proximally (PPAprox) or distally (PPAdist) to 
the occluding balloon. 0 ms denotes time of arterial occlusion. 175 ms denotes time constant 
for determination of pulmonary capillary pressure (Pcap) from the bi-exponentially fitted 
curve. 
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MYOGRAPHIC EXPERIMENTS  
All myographic experiments were conducted on vessels isolated form porcine lungs 
collected at regional abattoirs instantly after killing of the animals. The lungs were 
rinsed with a cold transport buffer solution and transported on ice to the laboratory 
within 1 h. Arterial and venous rings (internal circumference 2.6–15.2 mm, segment 
length 1.1–4.3 mm) were dissected under sterile conditions and subjected to immediate 
myographic experiments or after 24 h. After dissection, the vessel rings were placed in 
sterile Dulbecco’s Modified Eagle’s Medium supplemented with antibiotics and L–
glutamine until further experiments. The arterial and venous vessel rings were mounted 
on two parallel stainless steel pins in organ baths filled with Krebs-Ringer 
physiological salt solution continuously gassed with 95% O2 / 5% CO2 at a temperature 
of 37 ° C. One pin was connected to a force transducer and the other to a micrometer 
screw for length adjustment. Force data were collected with a computerized A/D 
converter. The vessels were stretched to the optimal circumference for maximal 
isometric force development [high K+ (80 or 125 mM)-induced contraction considered 
maximal]. This length was defined as the length (that is, circumference) at which the 
high potassium-induced contraction was maximal. In previous studies, this length was 
found to correlate with the initial slack circumference allowing an estimate of optimal 
length based on the slack circumference of the vessels186. After stretching and 
equilibration, the viability of the preparations was tested by measuring the contractile 
response to high K+. Preparations not contracting to K+ were excluded from the study. 
To assess endothelial function all preparations were challenged with U46619 (stable 
thromboxane A 2 analogue). After the contraction to this agonist had stabilized 
(approx. 5 min), bradykinin (arteries) or acetylcholine (veins) were added. Failure to 
relax to these two agonists (in the freshly isolated vessels) excluded the preparations 
from further experimentation. Constrictive agonists were added to the baths 
cumulatively and concentrations-response relationships were recorded. To assess 
endothelium-independent vasorelaxation, a separate set of precontracted incubated 
venous rings was exposed to cumulative concentrations (1 nM to 1 mM, log unit steps) 
of sodium nitroprusside (NO donor) and concentration-response relationships were 
recorded. The segment lengths of the preparations were recorded at the end of the 
experiments. Relaxation was calculated as percent of reduction of the active force at the 
stable plateau level. Contractile responses to high K+ were expressed as the ratio of 
force and segment length (active tension, mN/mm) and the other responses are 
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expressed as percentage of the maximal contraction induced by high K+. The force (Y) 
and concentration (X) data were analyzed by fitting a sigmoidal function using 
nonlinear regression (Prism 4.0; GraphPad Software Inc., La Jolla, CA., USA) using 
the formula: Y = Emax · Xh /(X h + EC50 h), where Emax denotes the estimated 
maximal amplitude of the response, h the steepness of the relationship (Hill coefficient) 
and EC50 the concentration giving half maximal response. 
 
ANALYSIS OF ET-RECEPTOR PROTEIN EXPRESSION WITH 
IMMUNOHISTOCHEMISTRY  
Approximately 10 mm long intact pieces of pulmonary vessels were transferred to 4 % 
paraformaldehyde for fixation for 24 h immediately after dissection or after 24 h 
exposure to endotoxin. After washing the vessels were embedded for cryosectioning (8 
µm sections). Sections were rehydrated, permeabilized and unspecific binding was 
blocked. This was followed by incubation with primary antibodies against for the ETA 
or ETB receptors and Cy3-conjugated smooth muscle α-actin. After washing, the 
sections were incubated with fluorescent secondary antibodies and finally incubated 
with nuclear stain DRAQ5, rinsed briefly and mounted with fluorescent mounting 
medium. The mounted sections were refrigerated dark until confocal microscopy 
analysis. 
 
ANALYSIS OF ET-RECEPTOR PROTEIN EXPRESSION USING 
IMMUNOBLOTTING 
Samples from pulmonary vessels were extracted in a protease inhibitor solution using a 
glass mortar and pestle for homogenization. When the tissue was completely dissolved, 
the extract was centrifuged and the supernatant was collected for protein determination. 
Tissue extracts was mixed with buffer, denatured, separated by polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. Ponceau staining was used 
to evaluate protein loading. Nonspecific binding sites were blocked by incubation with 
bovine serum albumin. Membranes were incubated with specific antibodies anti-ETA 
and ETB receptor respectively or mouse monoclonal antibody specific for smooth 
muscle-specific α-actin. After primary antibody incubation, membranes were washed 
and bands were visualized after incubation with a horseradish peroxidase-conjugated 
secondary antibody using ECL technique. Equal amounts of protein of the different 
samples were loaded on each gel and the band ECL intensities were measured using 
Material and Methods 
 
 
27 
GelDoc and an image software. Band intensities were expressed as percentage of the 
intensities of bands from freshly isolated vessels. 
 
STATISTICAL METHODS 
Data are presented as mean ± SEM. The statistical calculations were made using 
Statistica (version 7.0; StatSoft Inc., Tulsa, Oklahoma, USA). A p value of less than 
0.05 was considered statistically significant. 
 
Paper I and II 
Differences in contractions and relaxations between the in vitro preparations and 
between band intensities from Western blot were analyzed using Student’s t test. 
Concentration-response data were assessed using repeated measures analysis of 
variance (RM-ANOVA). Student’s t-test was used for analysis of within group effects 
induced by pharmacological challenge in vivo and RM-ANOVA was used for detection 
of effects of endotoxin (T0-T3) and effects of tezosentan treatment (T3-T4). 
Differences between groups and arterial and venous responses were analyzed with 
time-effect interactions. 
 
Paper III 
Normal distribution of data was analyzed using Kolmogorov-Smirnov test. In case of 
non-normal distribution, a logarithmic transformation was made to reach normal 
distribution of data. One-way univariate analysis with RM-ANOVA was used for 
analyzing changes over time in response to endotoxin from baseline until onset of 
intervention at 2 h. One-way ANOVA was used for evaluating differences between 
groups before onset of intervention at 2 h. The treatment effects were evaluated by one-
way ANOVA for group differences at each time point from 3 to 5 h, based on 
differences from the time point of 2 h. This ANOVA was followed by a post hoc 
analysis (Fisher least significant difference [LSD]). Correlation between ET-1-LI and 
MPAP was analyzed using the Spearman rank test. 
 
Paper IV 
Normal distribution of data was analyzed using Kolmogorov-Smirnov test. In case of 
non-normal distribution a logarithmical transformation was made to reach normal 
distribution of data. RM-ANOVA was used for analyzing changes over time in 
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response to endotoxin as well as differences between groups prior to onset of 
intervention (0-2 h). Effect of treatment was evaluated by two-way RM-ANOVA for 
group differences from three to five hours, using time point two hours as a covariate. 
Student´s t-test was used to analyze EVLWIGrav. Data from the experiments with ET-
challenge were analyzed using Friedman ANOVA followed by planed comparisons 
between treatment and baseline values. 
Results 
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SUMMARY OF RESULTS 
In vivo experiments 
Effects of endotoxin 
Systemically, endotoxin induced a hypodynamic response with decreased cardiac index 
(CI), mixed venous saturation (SVO2) and increased (paper I and IV) or unchanged (III) 
systemic vascular resistance index (SVRI). Mean arterial pressure (MAP) was 
unchanged (I and IV) or reduced (III). In all three in vivo studies, endotoxin induced a 
marked pulmonary arterial hypertension with increases in mean pulmonary arterial 
pressure (MPAP) and pulmonary vascular resistance index (PVRI). In the two studies (I 
and III) were Pcap was measured, endotoxin induced a dominant increase in pulmonary 
down-stream resistance (PdsVRI) and an increase in Pcap to levels well above those that 
have been reported to induce edema (Figure 7.). In line with these findings, EVLWI 
increased during endotoxemia when measured with STID (III and IV). This result was 
confirmed by gravimetrical analysis of EVLWI (IV). Moreover, endotoxemia induced a 
deterioration of pulmonary gas-exchange, seen as moderate reductions in P/F-ratio and 
with simultaneous increases in PaCO2. Concurrently, respiratory system compliance 
was reduced.  In all three studies, the animals developed a metabolic acidosis with 
decreased pH and BE. In addition, endotoxin administration induced a 
hemoconcentration seen as significant increases in Hb (III and IV). Arterial plasma 
levels of ET-1 increased more than two-fold in response to endotoxemia (III and IV). In 
paper IV endotoxin challenge evoked a marked increase in plasma-HBP (Figure 8.), 
whereas plasma-MPO was unchanged. 
 
 
Figure 7. Effect of inhaled or i.v. 
tezosentan (Tezo) on pulmonary 
capillary pressure (Pcap) during five 
hours of endotoxemia. 
Interventions given during 20 min 
after two hours. Striped bar 
illustrate endotoxin infusion time. 
Mean±SEM. * denotes p < 0.05 for 
inhaled tezosentan 0.5mg/kg 
versus control. 
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Systemic effects of dual ET-receptor antagonism during endotoxemia 
In paper I, tezosentan was administered systemically after three hours of endotoxemia 
as a 1 mg⋅kg-1 bolus and followed by a continuous infusion (1 mg⋅kg-1⋅h-1). In this 
setting tezosentan increased CI and reduced MAP, whereas no effect was noted on 
PAOP. In paper III, tezosentan was administered systemically as 0.5 mg⋅kg-1 bolus 
during 20 min after 2 h of endotoxemia. In this limited dosage, tezosentan did not 
induce any statistically significant changes in any systemic cardiovascular or 
biochemical parameters. However, plasma-ET-1 was markedly increased, indicating 
that a significant portion of ETB-receptor-mediated clearance of the ET-1 was blocked 
even by this modest dose of tezosentan.  
In paper IV a higher tezosentan dose was used, 1 mg⋅kg-1 bolus during 15 min followed 
by a continuous infusion of tezosentan 1 mg⋅kg-1⋅h-1 that persisted to the end of the 
experiment at 5 h. In this setting, tezosentan-treatment increased CI and reduced MAP 
as well as SVRI. HR was unchanged indicating that tezosentan-treatment caused an 
increased stroke volume. Moreover, tezosentan attenuated a further reduction of arterial 
pH and reduced arterial lactate. Due to inhibition of ETB-receptor-mediated clearance 
of ET-1, plasma-ET-1 increased more than four-fold in the tezosentan-treated group. 
Finally, tezosentan markedly counteracted the endotoxin-induced increase in plasma-
HBP (Figure 8.) and reduced hemoconcentration. 
 
 
 
Figure 8. Effect of i.v. tezosentan 
on plasma levels of heparin-
binding protein (HBP) during five 
hours of endotoxemia. Striped bar: 
endotoxin-infusion time, dotted bar 
tezosentan/vehicle administration 
time. Mean±SEM. * p < 0.05. 
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Pulmonary effects of dual ET-receptor antagonism during endotoxemia 
Tezosentan markedly reduced MPAP and PVRI (I, III and IV). This was seen with 
reductions in Pcap and PdsVRI (I). In paper III, tezosentan in a lower dose reduced Pcap 
and pulmonary up-stream vascular resistance index (PusVRI) while no statistically 
significant treatment effects were noted for PdsVRI. EVLWISTID was reduced by 
tezosentan-treatment (III and IV), a finding that was confirmed by analysis of 
EVLWIGrav at the end of the experiments in paper IV (Figure 9.). Tezosentan improved 
respiratory system compliance and increased SaO2, whereas neither the effects on P/F-
ratio nor PaCO2 reached statistical significance (IV). In paper III, where the low dose of 
tezosentan was used, no effects were seen on gas-exchange variables. 
 
 
 
 
 
 
Effects of inhaled dual ET-receptor antagonism during endotoxemia 
In paper III, the animals were exposed to five hours of endotoxemia. After two hours 
inhaled tezosentan was administered in two doses (0.05 and 0.5 mg⋅kg-1) during a 20 
minute period. This short term administration of a limited dose of tezosentan efficiently 
counteracted the endotoxin-induced pulmonary hypertension seen as a rapid decline in 
MPAP (Figure 10.) and PVRI. In addition, despite the short duration of the therapy, 
this effect was sustained over time. Inhaled tezosentan reduced Pcap and PusVRI. 
However, in this setting no statistically significant treatment effect of tezosentan were 
noted for PdsVRI. Inhaled tezosentan induced a reduction EVLWISTID, an effect that not 
Figure 9. Effect of i.v. tezosentan on extravascular lung water index (EVLWI) measured with A) 
single thermal indicator dilution (STID) and B) gravimetry (Grav) during five hours of 
endotoxemia. Striped bar illustrates endotoxin-infusion time, dotted bar illustrates tezosentan or 
vehicle infusion time. Mean±SEM. ** p < 0.01. 
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was sustained over time. Respiratory system compliance was improved by inhaled 
tezosentan, whereas no effects were noted on gas-exchange variables. In addition, 
inhaled therapy did not induce any statistically significant differences in MAP nor in 
any other systemic cardiovascular or biochemical parameters measured.  
Inhalation of tezosentan did not significantly affect systemic ET-1 levels compared 
with controls, suggesting a localized pulmonary effect of the compound. This was also 
reflected by the plasma concentrations of tezosentan, where inhalation of 0.05 mg⋅kg-1 
tezosentan gave almost 200-fold lower plasma level than i.v. treatment.  
 
 
 
Challenge with endothelin-1 and sarafotoxin 6c (I and IV) 
Infusion of ET-1 in non-endotoxemic animals reduced CI with simultaneous and 
marked increases in MAP and MPAP (I and IV). ET-1-challenge increased Pcap with a 
predominant increase in in PdsVRI (I, Figure 11A.). This was seen with a concurrent 
reduction in CrsI and a significant metabolic acidosis. WBC-count and plasma-MPO 
were not significantly changed in response to ET-1 (IV). However, plasma-HBP 
increased in a dose-dependent fashion in response to ET-1-challenge, to levels more 
than three-fold over baseline values (Figure 12.). After termination of the ET-1 
infusion, plasma-HBP readily tended to decrease. EVLWIGrav was slightly increased by 
ET-1 when compared to values from non-endotoxemic sham animals in previous 
reports147. However, the interpretation of this result is somewhat difficult as the lungs 
were extracted 90 min after termination of the challenge.  
Figure 10. Effect of inhaled or i.v. 
tezosentan (Tezo) on mean pulmonary 
artery pressure (MPAP) during five 
hours of endotoxemia. Intervention 
given during 20 min after two hours. 
Striped bar illustrate endotoxin infusion 
time. Mean±SEM.* p < 0.05 for 
respective interventions versus control.  
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ETB receptor stimulation by S6c led to significant increase in Pcap and analysis of 
vascular resistances showed a marked rise in downstream resistance (I, Figure 11B.). 
Finally, MAP and MPAP were unchanged while SVRI and PVRI were markedly 
augmented by S6c due to a reduction in CI. No measurements of EVLWI were made 
after S6c challenge in paper I. 
 
Challenge with phenylephrine (I) 
Infusion of phenylephrine (PHE) increased PusVRI but not PdsVRI (Figure 11C.). 
However, Pcap was significantly increased by PHE-infusion (Figure 11F.). These 
findings are explained by the simultaneous rise in pulmonary arterial occlusion pressure 
(PAOP) and a more pronounced increase in MPAP than Pcap induced by PHE. PHE did 
not affect CI while MAP and MPAP increased. 
 
Figure 11. Effect of endothelin-1 (ET-1, n=7), sarafotoxin 6c (S6C, n=6) and phenylephrine (PHE, 
n=10) infusion on vascular up and downstream resistances (A-C) and pulmonary capillary 
pressure (Pcap, D-F). Pulmonary upstream resistance (PusVRI, filled circles) and pulmonary 
downstream resistance (PdsVRI, open circles). Mean±SEM.* p <0.05, *** p < 0.001 versus 
baseline value.   
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In vitro experiments 
Reactivity of freshly isolated pulmonary vessels (I and II) 
The active wall tension (force per segment length) in response to depolarization with 
high K+ solution was similar in the freshly isolated, non-incubated, arteries and veins. 
No significant difference between arteries and veins was noted in response to the α2 
adrenergic agonist UK14.304, the thromboxane A 2 analogue U46619 or to PGF2α (II). 
ET-1 evoked responses in both pulmonary arteries and veins with maximal contractions 
observed at nmol∙L-1 concentrations. In the experiments of paper I, the venous response 
to ET-1 was significantly stronger than the arterial as measured by concentration effect 
interaction and by maximal contraction (Figure 13A). However, in paper II, the 
response to ET-1 was similar between the arterial and venous preparations. S6c induced 
a nearly two-fold stronger contraction and was active at lower concentrations in veins 
than in arteries (Figure 13B), a finding that was consistent between the two studies. 
PHE induced a contraction that was several-fold stronger in arteries than in veins (I and 
II, Figure 13C). In vessels preconstricted with U46619, the β-adrenergic agonist 
isoproterenol (ISO) induced a greater relaxation in veins compared to arteries (II). The 
responses to ACH were similar in the freshly isolated arteries and veins (II). 
 
Figure 12. Effect of graded endothelin-1 (ET-1) infusion on A) plasma levels of heparin-binding 
protein (p-HBP) and B) hemoglobin concentration. n=4. Mean±SEM. * p < 0.05 versus baseline 
values.   
Results 
 
  35 
 
 
 
 
Effects of incubation and endotoxin on vascular reactivity (II) 
Incubation during 24 h induced only modest and non-significant changes in active force 
generation of the vessels in response to membrane depolarization by high K+. In 
addition, no difference was found in response to the other constrictive substances apart 
from slightly augmented response to PHE in veins and a tendency towards an increase 
in response to S6c in arteries after incubation. In veins, incubation moderately 
attenuated the endothelium-dependent relaxation to ACH, while the artery was not 
significantly affected. Moreover, the relaxation induced by ISO, studied in arteries and 
veins and SNP, studied in vein only, was not altered by incubation.  
Incubation of the vessels in medium with added endotoxin to a concentration of 10 
mg⋅mL-1 during 24 h induced a significant decrease in the high K+ induced active 
tension of veins but not in arteries. Moreover, endotoxin also induced a markedly 
lowered reaction in both arteries and veins in response to PHE (Figure 14A). In veins 
selectively, the contraction induced by S6c and ET-1 was relatively augmented by 
endotoxin (Figure 14B and C), whereas the response to the other contractile agonists, 
except PHE, was unaltered in both preparations. The effects of the relaxing compounds 
ACH and ISO were not significantly changed by endotoxin, although there was a weak 
tendency suggesting a modest impairment of the endothelium-dependent relaxation of 
ACH in veins only. Endotoxin incubation did not change the response to the NO-donor 
sodium nitroprusside (SNP) in veins.  
 
Figure 13. Cumulative concentration-response relationships for A) endothelin-1, B) 
sarafotoxin 6c and C) phenylephrine on freshly isolated porcine pulmonary artery (filled 
circles) and vein (open circles) preparations. Mean±SEM. *** p < 0.001. 
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Expression of ET-receptors in vascular preparations (II) 
Immunohistochemistry was performed to localize the ETA and ETB receptors within the 
vascular tissue and to study the gross morphology of freshly isolated, incubated and 
endotoxin-incubated preparations. The vascular smooth muscle and the endothelial cell 
layer showed no signs of disruption or swelling after incubation or endotoxin exposure. 
Staining against α-actin showed equally intense staining in the smooth muscle cell layer 
of all preparations.  In fresh as well as in incubated vessels, the ETA receptors were 
preferentially located in the vascular smooth muscle cells, whereas the ETB receptors 
were located in the endothelial as well as the vascular smooth muscle cell layer. No 
difference in ET-receptor staining intensity or distribution could be detected between 
freshly isolated arteries and veins or between incubated and endotoxin-exposed vessels. 
The expression of ETA and ETB receptor protein was also investigated using Western 
blot and compared to α-actin protein levels. In arteries, the levels of both ETA and ETB 
receptor protein was higher compared to the levels in veins, using the same amount of 
protein loaded on the gel. This difference was not affected by incubation per se or by 
endotoxin. Moreover, no difference in expression of ET-receptor protein or α-actin was 
detected between freshly isolated, incubated or endotoxin-exposed vessels. 
Figure 14. A) In vitro responses in isolated porcine pulmonary arteries and veins, incubated 
with or without endotoxin (LPS). A) phenylephrine 10 µM, B and C) cumulative 
concentration-response relationships for endothelin-1 and sarafotoxin 6c. Mean±SEM. * p < 
0.05, ** p < 0.01. 
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DISCUSSION 
The vascular system was once seen as a rather inert transportation system for oxygen 
and nutrients dissolved in the blood. A new era begun during the 1980´s with the 
discoveries that showed that the endothelium was a highly active tissue that produced 
potent mediators of great importance during both health and disease. In sepsis, 
dysfunction of the vascular system is of vital importance. This thesis aimed to 
investigate mechanism of vascular dysfunction in a common and severe manifestation 
of sepsis, acute lung injury, with special reference to effects of the endothelin system. 
 
The porcine endotoxin model of sepsis induced lung injury 
A number of different models of lung injury have been described, all with their specific 
advantages, drawbacks and varying grades of clinical correlate187. To investigate one of 
the most common causes of lung injury, sepsis induced lung injury, the use of animal 
models is necessary as invasive monitoring, pharmacological interventions and not 
least the septic event itself, cannot safely or ethically be performed in humans.  
Over the years there has been a controversy on which animal model that best resembles 
the human sepsis syndrome, a debate that is still not resolved188,189. Animal sepsis 
models can be divided into three main categories based on the triggering event: 
exogenous administration of bacterial toxins, exogenous administration of viable 
bacteria, or inducing a damage of the animal’s natural barrier against bacteria 
(commonly done by ligating and puncturing of the cecum, allowing fecal peritonitis 
and bacterial translocation). All these models have their advantages and drawbacks. 
Bolus infusion of bacterial toxins or live bacteria often induces a powerful 
hypodynamic shock with high mortality. Models using fecal peritonitis have a strong 
clinical correlate in human abdominal infection and sepsis; however this development 
takes time (several hours to days) and the reproducibility is lower than in the other 
models.  
The reproducibility of the response to endotoxin infusion is superior compared with the 
other models, even though the potency of endotoxin may vary significantly between 
production-batches. In addition, endotoxin is a significant part of the pathophysiology 
of Gram-negative sepsis and the responses seen after administration of small doses of 
endotoxin to human volunteers are similar to those seen in human sepsis190. When the 
aim is to investigate and intervene in basic mechanisms of a biological phenomenon 
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such as sepsis, reproducibility and homogeneity is central, as great variability may 
conceal the effect of the intervention and necessitate the use of large numbers of 
animals. However, when basic findings later are to be transferred into new treatments, 
the resemblance of the model to the clinical condition becomes increasingly important. 
Studies using prolonged protocols and animals of high age would increase the 
resemblance to the clinical setting, but could be problematic due to ethical and financial 
aspects as well as the reproducibility of the experiments. 
The most common animal species that is used in medical science are rodents. They are 
relatively inexpensive to purchase and maintain and can therefore be used in large 
numbers. However, in sepsis research, the use of rodents has shortcomings as they are 
physiologically quite different from humans in terms of immunity, endotoxin-resistance 
and cardiovascular physiology. The physiology of pigs, especially regarding 
cardiovascular functions and the ET-system, is markedly more similar to human. In 
addition, the size of the animals permits extensive surgical preparation, monitoring and 
repeated blood-samplings - all important in sepsis research. 
 
Effects of systemic dual ET-receptor antagonism during endotoxemia (I, III and IV) 
As ET-1 is a powerful vascular constrictor, a striking but anticipated effect of systemic 
treatment with a dual ET-receptor antagonist was vasodilatation. MAP and SVRI were 
reduced by tezosentan in both paper I and IV. In paper III, no statistically significant 
effect of i.v. tezosentan, in a reduced dosage, was noted on MAP. The systemic 
vasodilatation caused an afterload reduction with ensuing increases in CI and SvO2 (IV).  
The effects on the pulmonary circulation were pronounced as MPAP and PVRI were 
efficiently and promptly reduced by tezosentan (III and IV). This finding emphasizes 
the pathophysiological importance of the ET-system in the pulmonary circulation 
during endotoxemia. Tezosentan reduced Pcap to levels less than 20 mmHg, a level that 
has been reported to be a threshold for edema formation37-38(I and III). This might be 
explained by the potent effect on PdsVRI which was reduced to non-endotoxemic levels 
(I). The changes in PusVRI and PdsVRI induced by endotoxemia were similar to the 
shifts seen in response to ET-1 and S6c challenge (I). These findings support the notion 
that endotoxemia-induced changes in pulmonary vascular resistance are mediated, at 
least partly, by ET-receptor stimulation. In paper III tezosentan i.v. failed to affect the 
relation between PusVRI and PdsVRI. This discrepancy may in part be explained by the 
significantly higher dose of tezosentan used in paper I. Moreover, the downstream 
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predominance seemed to wear off by 5 h, suggesting that this might be a transient 
phenomenon and that an earlier intervention might induce a more prominent effect in 
the used endotoxin model. 
Tezosentan administered intravenously in higher and prolonged doses has previously 
been shown to improve oxygenation in endotoxemia191. However, in the present 
experiments only a limited improvement in gas-exchange was achieved by tezosentan 
treatment. This difference could possibly be attributed to differences in the degree of 
gas-exchange disturbance compared to the previous study. 
 
Effects of systemic dual ET-receptor antagonism on HBP and EVLW during 
endotoxemia (IV) 
No significant increase of plasma-HBP was seen in response to surgery during the 
preparation of the animals. In contrast, endotoxin infusion induced a three-fold increase 
of plasma-HBP after three hours, reflecting a significant activation and degranulation of 
PMNs. However, as plasma-MPO was unchanged, this degranulation seems to be 
partly selective. Possibly, this difference could be due to the different granule subsets 
which contain these proteins. The increase in HBP was similar to what has been shown 
in patients with septic shock164. Simultaneously with the increase in HBP, hemoglobin 
concentration as well as EVLWISTID increased. This suggests that endotoxin induced a 
vascular hyperpermeability with substantial leakage of plasma water to extravascular 
tissue. Systemic tezosentan-treatment counteracted these changes; markedly attenuated 
endotoxin-induced elevation of plasma-HBP levels, reduced EVLWISTID and 
hemoglobin concentration. Concurrently, CrsI increased and gas-exchange tended to 
improve, indicating that pulmonary edema was reduced. After termination of the 
experiment, gravimetrical analysis of EVLWI confirmed these findings. Together these 
results suggest that tezosentan, directly or indirectly, reduces plasma-HBP and 
simultaneously attenuate formation of pulmonary edema. To clarify whether these 
phenomena are results of indirectly or directly acting mechanisms, experiments using 
isolated preparations would be of value.  
 
Effects of inhaled dual ET-receptor antagonism during endotoxemia (III) 
In paper III, tezosentan was delivered as a bolus inhalation in two different doses, 0.05 
and 0.5 mg∙kg-1. Inhalation increased plasma concentrations of tezosentan in a dose 
dependent manner, where low-dose inhalation led to plasma concentrations that were 
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approximately 10-fold lower than those achieved with the higher dose. Furthermore, 
the concentrations after i.v. treatment were almost 20-fold higher (714 versus 37 
ng∙mL-1) than after inhalational treatment of an equivalent dose. As intra-pulmonary 
clearance of tezosentan is unlikely, this difference suggests that only a minor portion of 
the substance reached parts of the lungs were systemic uptake could take place. 
However, although the amount of inhaled tezosentan that reached the systemic 
circulation was very low, the biological effects were highly significant, even for the 
lower inhalation-dose. Both inhaled doses distinctively reduced MPAP and PVRI. In 
addition, a dose-dependent difference in response was noted for Pcap where only the 
higher inhaled tezosentan dose had significant effects. The effect was marked and Pcap 
was reduced to levels less than the reported threshold for edema formation. EVLWISTID 
were reduced by both systemic and inhaled tezosentan, but only inhaled treatment 
counteracted the endotoxin-induced reduction in respiratory compliance. Part of this 
effect could be due to counteraction of ET-1 mediated bronchoconstriction192,  possibly 
inhalation may be more efficient in reaching bronchial ET-receptors as compared with 
systemic treatment. 
There was no significant improvement in gas-exchange parameters by inhaled 
tezosentan in our endotoxin-model. Other investigators have reported improved 
oxygenation in porcine, bronchial lavage-induced, lung injury using inhaled selective 
ETA-receptor antagonist193. However, direct comparisons are problematic as the 
intervention in that study was started immediately after induction of lung injury and 
given during one hour. Moreover, endotoxin-induced lung injury induces a more 
limited and unpredictable degree of gas-exchange disturbance than the lavage induced 
model. This may have contributed to the lack of effects on oxygenation in response to 
inhaled tezosentan treatment.  
 
Pharmacological reactivity of freshly isolated pulmonary vessels (I and II) 
Myographic experiments on isolated, non-incubated, porcine pulmonary vessels 
revealed a relatively diversified pattern of responses to pharmacological stimuli. α1 
adrenergic stimulation with PHE induced a more than 5-fold stronger contraction in 
pulmonary arteries than veins.  
ETB receptor stimulation with S6c had a predominant constrictive effect in pulmonary 
veins, whereas only a minor response was noted in pulmonary arteries. This finding, 
which is in line with previous reports194,195, suggests that ETB receptor mediated effects 
Discussion 
 
  41 
could be a determinant of differential responses to ET in pulmonary arteries and veins. 
The differential effects of the ET system on the pulmonary vascular tone have 
previously been investigated in various species, partly with conflicting results. In 
humans196 and in other spices197,198, the pulmonary vein has been suggested to be more 
sensitive than the artery to ET-1 induced constriction. However, other authors have 
found no difference194,199. Our findings do not give the final answer due to partly 
conflicting results. In paper I, there was moderate but significant difference between 
pulmonary arteries and veins, with a predominant constriction in veins in response to 
ET-1 stimulation. This finding could not be repeated in paper II where we found no 
difference in response to ET-1 stimulation. The causes of this discrepancy are unclear 
but differences in vessel size could be one possible explanation. 
 
Effects of endotoxin on vascular reactivity and ET-receptor expression in vitro (II) 
The myographic experiment on isolated vascular preparations showed that endotoxin 
induces differentiated effects on porcine pulmonary arteries and veins. In this setting, 
endotoxin caused a lowered response to α1-adrenergic stimulation, with a predominant 
effect in arteries. Concurrently, endotoxin induces a relative augmentation of the 
contractile response to both ET-1 and S6c in pulmonary veins, without altering any 
apparent expression or distribution of ET-receptors. Taken together, these endotoxin-
induced changes in arterial and venous contractile responses to the adrenergic and ET 
pathways can, especially in states with increased sympathetic activity and high ET 
levels, influence the balance in tone between pulmonary arteries and veins. In turn, 
these disturbances could lead to an increase in Pcap and edema formation, particularly 
when capillary permeability is increased and intravascular oncotic pressure is reduced. 
 
Effects of ET-receptor subtype stimulation in vivo (I and IV)  
Infusion of ET-1 in non-endotoxemic animals induced a marked increase in systemic 
and pulmonary vascular resistances, reflecting the powerful vasoconstrictive properties 
of ET-1 (I and IV). Simultaneously Pcap was increased with a predominant rise in 
PdsVRI (I). Measurements of Pcap during S6c infusion led to marked increases in 
PdsVRI. However, as S6c simultaneously decreased CI, Pcap was less augmented by S6c 
than ET-1 (I).  
ET-1-challenge increased plasma levels of HBP in a dose-dependent manner, to levels 
more than three-fold over baseline values. Concurrently, CrsI was reduced and Hb 
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tended to increase. These results suggest that ET-1 potentially increases both the 
pulmonary capillary hydrostatic pressure and, via HBP and possibly other mediators, 
the permeability of the pulmonary capillaries. In addition, reports from other authors 
have suggested that ET-1 also might interfere with alveolar fluid clearance200,201. 
Together, these results suggest that ET-1 can promote edema formation through some 
quite diverse mechanisms. In our experiments, EVLW was slightly increased (8.2±1.1 
mL∙kg-1) after ET-1-challenge compared to previously reported values (6.6±0.2 mL∙kg-
1) from sham experiments202. However, the gravimetrical measurement was performed 
90 min after termination of the ET-1 infusion and it cannot be excluded that some 
reabsorption of EVLW occurred during this time period. Continuous measurements of 
EVLW with STID-technique might have given additional information but were not 
performed in these experiments. 
ET-1 has previously been reported to increase capillary permeability in isolated lung 
preparations, changes that required the presence of leukocytes and plasma203, 
suggesting that the permeability promoting effect of ET-1 is mediated through 
leukocyte-dependent factors. In our study, infusion of ET-1 induced a rapid, 
pronounced and dose-dependent increase in HBP-levels. After termination of the ET-1 
infusion, HBP tended to decrease quite rapidly. Our interpretation is that ET-receptor 
stimulation triggers a reaction which subsequently activates PMNs and promptly 
induces secretion of HBP. Whether this reaction is directly mediated via stimulation of 
ET-receptors on PMNs, or indirect through other inflammatory mediators, remains to 
be clarified. Moreover, as ET-1 is a dual ET-receptor agonist these experiments do not 
answer which ET-receptor subtype that is responsible for the increase in HBP.  
Preliminary and unpublished data from our laboratory show that also infusion with the 
selective ETB-agonist S6c increases plasma levels of HBP. This suggests that the ETB-
receptor is involved in the process leading to HBP release. However, as only the 
expression of ETA-receptors has been described in human PMNs204 indirect 
mechanisms may well be involved in the interaction between ET-receptor stimulation 
and HBP-release. To clarify the effect of the two ET-receptors on HBP secretion 
further, in vivo and in vitro studies using selective antagonists and agonists are needed. 
 
Effects of α1-adrenergic stimulation in vivo (I) 
Infusion of the selective α1-adrenergic agonist phenylephrine (PHE) increased Pcap. 
However, as PHE also augmented PAOP and relatively increased MPAP more than 
Discussion 
 
  43 
Pcap, analysis of vascular resistances showed that PHE predominately increased PusVRI. 
Systemically, PHE increased MAP while CI was unchanged. The increase in Pcap was 
significant but Pcap did not reach the alleged threshold for hydrostatic edema formation. 
Measurements of lung water would have been interesting in these experiments but was 
not performed as edema formation was not of primary interest in that study. 
 
SUMMARY AND FUTURE PERSPECTIVES 
In summary, our findings show that endotoxemia predominately increases pulmonary 
downstream resistance which subsequently augments pulmonary capillary hydrostatic 
pressure. In addition, endotoxin induces a degranulation of PMN which increases 
plasma levels of permeability and edema promoting HBP. These endotoxin-induced 
changes in capillary filtration pressure and levels of permeability promoting mediators 
increase pulmonary edema. Systemic treatment with tezosentan, a dual ET-receptor 
antagonist, markedly counteracts these changes and reduces pulmonary edema. In 
addition, inhaled tezosentan efficiently and selectively reduces pulmonary hypertension 
during endotoxemia. Taken together, these results show that the endothelin system is 
extensively involved in the pathophysiology of endotoxin-induced lung injury. These 
findings need to be further elucidated, in other experimental conditions and in humans. 
As numerous large scale trials has failed to translate promising therapeutical 
interventions from animal sepsis models to the clinical setting, the hunt for new 
treatments of sepsis has been called “the graveyard of pharmaceutical companies” 205. 
The difficulties in transferring effective candidate treatments to the septic patient reflect 
the complexity of the syndrome and possibly the shortcomings of the often used animal 
models. However, despite these difficulties, research on the mechanisms of sepsis is 
highly relevant and new treatments are needed. To increase the probability of 
successful transfer of novel treatments from animals to patients, candidate therapeutics 
need to be evaluated in different models of sepsis and when clinically tested, patient 
selection and timing of treatment is of greatest importance. These factors would 
undoubtedly be of high significance when it comes to the possible future use of ET-
antagonists in sepsis and lung injury. Selection of patients is then crucial but this 
increase the difficulty with adequate sizing in the studies. In addition, as the course of 
sepsis is a highly dynamic, proper timing of intervention is of marked importance. 
Another question is dosing and the way of administration of ET-antagonists. Our 
results suggest that inhaled therapy permits treatment in reduced dosages, especially if 
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the primary aim is to reduce pulmonary hypertension. Naturally, the safety of inhaled 
therapy with ET-antagonists needs to be fully ascertained before trials in patients can be 
performed.
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CONCLUSIONS 
⋅ Selective ETB-receptor stimulation increases pulmonary vascular down-stream 
resistance and pulmonary capillary pressure in vivo. 
 
⋅ Selective ETB-receptor stimulation constricts isolated pulmonary veins more 
than arteries in vitro. 
 
⋅ Endotoxin-infusion predominantly increases pulmonary down-stream 
resistance and increases in pulmonary capillary pressure in vivo. 
 
⋅ Endotoxin increases the constrictive response to selective ETB-receptor 
stimulation in pulmonary veins and reduces the constrictive response to 
adrenergic α1 receptor stimulation in pulmonary vessels in vitro.  
 
⋅ Endotoxin incubation does not change ET-receptor subtype expression or 
distribution in isolated pulmonary vessels.  
 
⋅ Systemic dual ET-receptor antagonism reduces pulmonary capillary pressure 
and pulmonary downstream vascular resistance during endotoxemia.  
 
⋅ Inhaled dual ET-receptor antagonism efficiently and selectively counteracts 
endotoxin induced pulmonary hypertension.   
 
⋅ Systemic dual ET-receptor antagonism reduces plasma levels of edema 
promoting heparin-binding protein and formation of extravascular lung water 
during endotoxemia.  
 
⋅ ET-receptor stimulation increases extravascular lung water and dose-
dependently increases plasma levels of edema promoting heparin-binding 
protein.
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APPENDIX 
 
Gravimetrical analysis of extravascular lung water according to Pearce et al: 
Calculation of erythrocyte cell mass of the lung:  
 
𝑄𝑟 = 𝑄ℎ × �𝐻𝑏𝑠
𝐻𝑏𝑏
� × �𝐹𝑤ℎ
𝐹𝑤𝑠
� × 𝐻𝑐𝑡 
Qr erythrocyte cell mass of the lung 
Qh weight of lung homogenate 
Hbs hemoglobin concentration of supernatant 
Hbb hemoglobin concentration of whole blood 
Fwh fractional water content of homogenate (= (wet - dry) / wet) 
Fws fractional water content of supernatant 
Hct hematocrit of blood sample 
 
 
Residual blood content of the lung is the sum of erythrocyte cell mass and 
plasma mass: 
 
𝑄𝑏 = 𝑄𝑟 + 𝑄𝑟 × �1− 𝐻𝑐𝑡
𝐻𝑐𝑡
� 
Qb residual blood content of the lung 
 
 
Extravascular lung water content of the lung: 
 
𝑄𝑤𝑙 = 𝑄ℎ × 𝐹𝑤ℎ × 𝑄𝑏 × 𝐹𝑤𝑏 − 𝑄𝑤𝑡 
Qwl extravascular lung water 
Fwb fractional water content of blood 
Qwt weight of water added during homogenization 
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Calculations of pulmonary vascular resistances: 
 
𝑃𝑉𝑅𝐼 = 𝑀𝑃𝐴𝑃 − 𝑃𝐴𝑂𝑃
𝐶𝐼
 
 
𝑃𝑢𝑠𝑉𝑅𝐼 = 𝑀𝑃𝐴𝑃 − 𝑃𝑐𝑎𝑝
𝐶𝐼
 
 
𝑃𝑑𝑠𝑉𝑅𝐼 = 𝑃𝑐𝑎𝑝 − 𝑃𝐴𝑂𝑃
𝐶𝐼
 
PVRI pulmonary vascular resistance index 
MPAP mean pulmonary artery pressure 
PAOP pulmonary artery occlusion pressure 
CI cardiac index 
Pcap pulmonary capillary pressure 
PusVRI pulmonary upstream vascular resistance index 
PdsVRI pulmonary downstream vascular resistance index  
   
 
 
